Paclitaxel vs Epidoxorubicin plus Paclitaxel as Second-Line Therapy for Platinum-Refractory and -Resistant Ovarian Cancer

By Bolis G.   Parazzini F.   Scarfone G.   Villa A.   Amoroso M.   Rabaiotti E.   Polatti A.   Reina S.   Pirletti E.  

Gynecologic Oncology, Vol. 72, Iss. 1, 1999-01 ,pp. : 60-64

Elsevier

Access to resources Recommend Favorite

Tamoxifen in Platinum-Refractory Ovarian Cancer: A Gynecologic Oncology Group Ancillary Report

By Markman M.   Iseminger K.A.   Hatch K.D.   Creasman W.T.   Barnes W.   Dubeshter B.  

Gynecologic Oncology, Vol. 62, Iss. 1, 1996-07 ,pp. : 4-6

Academic Press

Access to resources Recommend Favorite

Altretamine (Hexamethylmelamine) in Platinum-Resistant and Platinum-Refractory Ovarian Cancer: A Gynecologic Oncology Group Phase II Trial

By Markman M.   Blessing J.A.   Moore D.   Ball H.   Lentz S.S.  

Gynecologic Oncology, Vol. 69, Iss. 3, 1998-06 ,pp. : 226-229

Elsevier

Access to resources Recommend Favorite

A phase II study of capecitabine in the treatment of ovarian cancer resistant or refractory to platinum therapy: a multicentre Italian trial in ovarian cancer (MITO-6) trial

By Pisano Carmela   Morabito Alessandro   Sorio Roberto   Breda Enrico   Lauria Rossella   Gebbia Vittorio   Scaltriti Laura   Scalone Simona   Zagonel Vittorina   Greggi Stefano   Beneduce Gerardo   Losito Simona   Gallo Ciro   Maio Massimo   Forestieri Valeria   Pignata Sandro  

Cancer Chemotherapy and Pharmacology, Vol. 64, Iss. 5, 2009-10 ,pp. : 1021-1027

Springer Publishing Company

Access to resources Recommend Favorite

Long-Term Survival with Whole Abdominopelvic Irradiation in Platinum-Refractory Persistent or Recurrent Ovarian Cancer

By Cmelak A.J.   Kapp D.S.  

Gynecologic Oncology, Vol. 65, Iss. 3, 1997-06 ,pp. : 453-460

Elsevier

Access to resources Recommend Favorite